Effect of BMS-914392 on Pharmacokinetics of Metoprolol

• Status: Completed
• Trial end date: 2010-11-01
• Target enrollment: 0
• Participant gender: All

Summary

The purpose of the study is to assess the effects of BMS-914392 administration on the pharmacokinetics of a single-dose of metoprolol in healthy subjects.

• Phase: Phase 1
• Accepts Healthy Volunteers?: Accepts Healthy Volunteers

Details

• Lead Sponsor: Bristol-Myers Squibb
• Collaborator: PRA Health Sciences
• Treatments: Metoprolol

Criteria

Inclusion Criteria:

• Healthy subjects as determined by no clinically significant deviation from normal in medical history, physical examination, ECGs, and clinical laboratory determinations.

• Subjects genotyped as Intermediate, Extensive or Ultra-rapid CYP2D6 metabolizers

• Women of childbearing potential (WOCBP) and men must be using an acceptable method of contraception to avoid pregnancy

Exclusion Criteria:

• Any significant acute or chronic medical illness.

• Current or recent (within 3 months of study drug administration) gastrointestinal disease.

• Current or history of neurological diseases or psychiatric disorders, cardiovascular diseases, and bronchospastic diseases.

• CYP2D6 poor metabolizers based on genotype